Skip to main content

Table 1 Characteristics of 6 trials included in this meta-analysis

From: Immune checkpoint inhibitors plus neoadjuvant chemotherapy in early triple-negative breast cancer: a systematic review and meta-analysis

Source Year Journal Phase Treatment No. of patients Median age Primary endpoints pCR in ITT(%)
KEYNOTE-522, Schmid et al. [17] 2020 New England Journal of Medicine 3 E:Pembro+pac + Cb → AC
C:pbo + pac + Cb → AC
784
390
49(22–80)
48(24–79)
pCR and EFS in ITT 64.8(260/401)
51.2(103/201)
GeparNuevo study, Loibl et al. [19] 2019 Annals of Oncology 2 E:Durva+nab-pac → EC
C:Pbo + nab-pac → EC
88
86
49.5(23–76) pCR in ITT 53.4(47/88)
44.2(38/86)
NeoTRIPaPDL1, Gianni et al. [21] 2019 Cancer Research 3 E:Atezo+Cb + nab-pac C: Cb + nab-pac 138
142
50 EFS 43.5(60/138)
40.8(58/142)
I-SPY2 Trial, Nanda et al. [18] 2020 JAMA oncology 2 E:Pembro+pac → AC C:Pbo + pac → AC 29
85
50(27–71)
47(24–77)
pCR in ITT 60(17/28)
22(17/79)
Impassion031, Elizabethet al. [20] 2020 The Lancet 3 E:Atezo+nab-pac → AC
C:Pbo + nab-pac → AC
165
168
51(22–76)
51(26–78)
pCR in ITT and in PD-L1+ populations 57.6(95/165)
41.1(69/168)
Nci 10,013, Foluso et al. [22] 2021 Cancer Research 2 E:Atezo+pac + Cb C:Pac + Cb 45
22
52(25–78) pCR and TIL percentages in ITT 55.6(25/45)
18.8(3/16)
  1. E Experimental, C Control, pCR pathological complete response, EFS event-free survival, ITT intention-to-treat populations, PD-L1+ programmed death ligand 1 positive